Search
Quinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnQuinagolide is currently available in several countries including Canada, but not approved for treatment in the United States. … Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer.
Synonyms: (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamideTizanidine
go.drugbank.com/drugs/DB00697ApprovedInvestigationalInitially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons … It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.
Mixtures: MYOS -NOR F TABLETASSuprofen
go.drugbank.com/drugs/DB00870ApprovedWithdrawnIt is no longer approved for use in the United States.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticThrombin
go.drugbank.com/drugs/DB11300ApprovedInvestigationalThrombin requires no intermediate physiological agent for its action. It clots the fibrinogen of the blood directly. … Medical thrombin is a protein substance produced through a conversion reaction in which prothrombin of bovine origin is activated by tissue thromboplastin in the presence of calcium chloride.
Eteplirsen
go.drugbank.com/drugs/DB06014ApprovedInvestigationalEteplirsen directly works on the DMD gene to promote dystrophin production. Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] … [L40015] Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory or cardiac complications.
Synonyms: N-dimethylphosphonamidate) RNA, dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a→5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G),5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,Pegloticase
go.drugbank.com/drugs/DB09208ApprovedInvestigational[L42425] Pegloticase was approved by the FDA in 2014, and in 2022, the drug label included the co-administration of pegloticase and methotrexate.[L42425] … Pegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies.
Glipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigationalAccording to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. … [L6712] Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed
Synonyms: N-{4-[β-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylureaIcosapent
go.drugbank.com/drugs/DB00159ApprovedInvestigationalNutraceuticalImportant polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovas...
Mixtures: UltimateCare ONE NFCategories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Non COX-2 selective NSAIDSSimethicone
go.drugbank.com/drugs/DB09512ApprovedInvestigational[A228308] It has a favourable safety profile as it is not systemically absorbed.[A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308] … Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination.
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune … Rilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies.